A RARE CASE OF COEXISTING BLADDER SMALL CELL NEUROENDOCRINE CARCINOMA AND PROSTATE ADENOCARCINOMA: CASE REPORT AND LITERATURE REVIEW
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Abstract
Objective: We present a case of synchronous malignancies of rare bladder small cell neuroendocrine carcinoma (SCNC) and prostate adenocarcinoma and provide literature review of bladder SCNC. Case(s) presentation: A 72-year-old male smoker presented with 3 months history of gross hematuria. Ultrasonography showed a large hypoechoic mass in the right bladder. TURBT was performed and histopathology of the TURBT specimen showed a high-grade papillary urothelial carcinoma. Abdominal contrast-enhanced computed tomography (CECT) demonstrated an isodense heterogenous undefined mass, with irregular border at right anterolateral side of bladder wall. Radical cystoprostatectomy, bilateral radical lymph node dissection and bilateral ureterocutaneostomy was performed. Histopathology and immunohistochemical examination after radical cystoprostatectomy revealed bladder small cell neuroendocrine carcinoma coexisting with prostate adenocarcinoma (Gleason score 3+3=6, group 1). The patient eventually succumbed to disease after having symptomatic disease progression and metastatic disease five months after the surgery. Discussion: Bladder SCNC is a rare malignancy with an incidence of 1–9/1,000,000 reported. This tumor has an aggressive clinical course with high incidence of metastasis, and it tends to confer dismal prognosis. No specific clinical symptom exists. Histopathological recognition and immunohistochemistry is required to differentiate this rare entity. Conclusion: Clinicians and pathologists should be alert to the possibility of bladder SCNC despite extremely scarce incidence. Keywords: Bladder cancer, small cell neuroendocrine carcinoma, synchronous malignancy, case report.
##plugins.themes.bootstrap3.article.details##
bladder cancer, small cell neuroendocrine carcinoma, synchronous malignancy, case report
Bruins HM, Djaladat H, Ahmadi H, Sherrod A, Cai J, Miranda G, et al. Incidental prostate cancer in patients with bladder urothelial carcinoma: Comprehensive analysis of 1,476 radical cystoprostatectomy specimens. Journal of Urology. 2013; 190(5): 1704–9.
Singh S, Ahuja A, Sardana R, Singla A. Pure Small Cell Neuroendocrine Carcinoma of Urinary Bladder: a Rare Entity. Indian J Surg Oncol. 2020 Sep 1; 11: 282–5.
Kassas JM, Fiuk J v, Brenner CA. Primary Small Cell Carcinoma of the Bladder. Cureus. 2021: 13(5): e15146.
Jung K, Ghatalia P, Litwin S, Horwitz EM, Uzzo RG, Greenberg RE, et al. Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective Review. Clin Genitourin Cancer. 2017 Jun 1; 15(3): e337–43.
Li Z, Lin C, Wang D, Xie J, Zhou C, Chen P, et al. Primary small cell neuroendocrine carcinoma of the urinary bladder: A rare case and a review of the literature. Mol Clin Oncol. 2018; 9(3): 335-338.
Masood B, Iqbal N, Iqbal W, Masood Y, Akbar MK, Mamoon N. Small-cell neuroendocrine carcinoma of the urinary bladder: A case report. Int J Health Sci. 2020; 14(2): 53–5.
Bayrak BY. The Clinical and Uropathological Aspects of Neuroendocrine Tumours of the Bladder: A Review. Journal of Urological Surgery. 2021 Mar 1; 8(1): 1–7.
Wang G, Xiao L, Zhang M, Kamat AM, Siefker-Radtke A, Dinney CP, et al. Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. Hum Pathol. 2018 Sep 1; 79: 57–65.
Zhao X, Flynn EA. Small cell carcinoma of the urinary bladder a rare, aggressive neuroendocrine malignancy. Vol. 136, Archives of Pathology and Laboratory Medicine. 2012. p. 1451–9.
Virarkar M, Vulasala SS, Gopireddy D, Morani AC, Daoud T, Waters R, et al. Neuroendocrine Neoplasms of the Female Genitourinary Tract: A Comprehensive Overview. Cancers. 2022; 14(13): 3218.
la Croce G, Naspro R, Finati M, Pellucchi F, Sodano M, Manica M, et al. The Accuracy of Transurethral Bladder Resection in Detecting Bladder Cancer Histological Variants and Their Prognostic Value at Radical Cystectomy. J Clin Med. 2022 Feb 1; 11(3): 550.
Kouba E, Cheng L. Neuroendocrine Tumors of the Urinary Bladder According to the 2016 World Health Organization Classification: Molecular and Clinical Characteristics. Endocrine Pathology. Humana Press Inc.; 2016; 27: p. 188–99.
Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF, et al. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. Journal of Clinical Oncology. 2009 Jun 1; 27(16): 2592–7.
Bhatt VR, Loberiza FR, Tandra P, Krishnamurthy J, Shrestha R, Wang J. Risk factors, therapy and survival outcomes of small cell and large cell neuroendocrine carcinoma of urinary bladder. Rare Tumors. 2014; 6: 10–4.
Dorff TB, Quinn DI. Small cell carcinoma of the bladder. Uptodate. 2022.
Flaig TW, Spiess PE, Chair V, Abern M, Agarwal N, Bangs R, et al. NCCN Guidelines Version 2. Bladder Cancer. 2022.
Kaushik D, Frank I, Boorjian SA, Cheville JC, Eisenberg MS, Thapa P, et al. Long-term results of radical cystectomy and role of adjuvant chemotherapy for small cell carcinoma of the bladder. International Journal of Urology. 2015 Jun 1; 22(6): 549–54.
Akamatsu H, Nakamura K, Ebara T, Inaba K, Itasaka S, Jingu K, et al. Organ-preserving approach via radiotherapy for small cell carcinoma of the bladder: an analysis based on the Japanese Radiation Oncology Study Group [JROSG] survey. J Radiat Res. 2019 Jul 1; 60(4): 509–16.
Hoffman-Censits J, Choi W, Bivalacqua TJ, Pierorazio P, Kates M, Lombardo K, et al. Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective Experience. Clin Genitourin Cancer. 2021 Apr 1; 19(2): 176–81.